Loading
A phase 2 trial of GRN-1201 run by BrightPath Biotherapeutics, terminated.
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC is a phase 2 interventional study registered as NCT03417882 by BrightPath Biotherapeutics, with 20 participants enrolled, started 2019-01-03. Conditions recorded: Metastatic NSCLC. Interventions recorded: GRN-1201 + Pembrolizumab.
Shares GRN-1201, BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/